Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Company Description
Lions Gate makes motion pictures, television programming and syndication. The company operates through two segments, Motion Pictures and Television Production. The company distributes a library of approximately 13,000 motion picture titles, television episodes, and programs directly to retailers, rental kiosks, and pay and free television channels through various digital media platforms in the United States, Canada, the United Kingdom, and Ireland, as well as indirectly to other international markets through its subsidiaries and various third parties. It also produces and syndicates 19 television shows, which air on 14 networks and distributes in approximately 200 series worldwide. Lions Gate was founded in 1986 and is headquartered in Santa Monica, California.
Lions Gate Beats Estimates in Two of Three Quarters
Lions topped the Zacks Consensus Estimate in two of the last three quarters. The March 2012 quarter saw the company post a beat of $0.03 or 16% ahead of the Zacks Consensus Estimate. Following this beat, the stock rose 3.2% in the session after the release.
The Septemeber 2012 quarter was the most recent report and the beat was nothing short of stunning. The company reported earnings per share of $0.53 when the Zacks Consensus Estimate called for $0.08. That meands a beat of $0.45 or 562%! The stock traded higher by more than 10% in the trading session following the release.
Lions Gate Sees Revenue Increases
In both quarters that saw positive earnings surprises, the company was able to post beats on the top line as well. The March 2012 quarter had revenue come in at $645M, about $3M more than the Zacks Consensus Estimate. The September quarter saw revenue of $707M, $89M or 14% more than the Zacks Consensus Estimate.
Toll Brothers Sees Estimates Moving Higher
Estimates for Lions Gate have been rising of late. The Zacks Consensus Estimate for 2012 for Toll Brothers stood at $0.54 as of February 2012. The consensus since moved higher to $0.42. Over the same time period estimates for 2013 have moved from $0.61 to $1.42. The implied earnings growth rate of more than 48% is just what aggressive growth investors are seeking.
Valuation
Lions Gate trades higher than the industry average for nearly every metric that aggressive growth investors tend to focus. The trailing twelve months PE of 39x is skewed due to some recent negative earnings. The forward earnings multiple of 20x is much more in line with the industry average of 16x. The price to book multiple, a more conservative measure, is 18x and well ahead of the industry average of 3x. The price to sales multiple of 1.2x is less than half of the 2.5x industry average.
The Chart
A quick look at the price and consensus chart shows a stock that has rallied throughout 2012. Analyst estimates continue to rise for the stock and the gaps between the years show the growth of earnings. As the earnings estimates continue to increase, the price of the stock is following in lock step. Lions Gate is a Zacks #1 Rank (Strong Buy).
Brian Bolan is a Stock Strategist for Zacks.com. He is the Editor in charge of the Zacks Home Run Investor service, a Buy and Hold service where he recommends the stocks in the portfolio
Brian is also the editor of Follow The Money Trader a trading service that tracks institutional money flows and looks for great stock picks from that data.
Follow Brian Bolan on twitter at @BBolan1
Like Brian Bolan on Facebook
Read the full reports :
Analyst Report on LGF